A Propósito de um Caso de Síndrome Hipereosinofílica Idiopática Tratada com Mepolizumab

Margarida Gomes; Sofia Ferreira; Ana Mendes; Tiago Marques; Sara Silva

doi:10.20344/amp.23406

A Case of Idiopathic Hypereosinophilic Syndrome Treated with Mepolizumab

Authors

Margarida Gomes Serviço de Imunoalergologia. Unidade Local de Saúde Santa Maria. Lisboa.
Sofia Ferreira Serviço de Imunoalergologia. Hospital Dr. Nélio Mendonça. Funchal.
Ana Mendes Serviço de Imunoalergologia. Unidade Local de Saúde Santa Maria. Lisboa.
Tiago Marques Serviço de Infecciologia. Unidade Local de Saúde Santa Maria. Lisboa. & Centro Académico de Medicina de Lisboa. Faculdade de Medicina. Universidade de Lisboa. Lisboa.
Sara Silva Serviço de Imunoalergologia. Unidade Local de Saúde Santa Maria. Lisboa. & Centro Académico de Medicina de Lisboa. Faculdade de Medicina. Universidade de Lisboa. Lisboa.

DOI:

https://doi.org/10.20344/amp.23406

Keywords:

Antibodies, Monoclonal, Humanized, Hypereosinophilic Syndrome/drug therapy

Abstract

n/a.

Downloads

Download data is not yet available.

References

Gotlib J. World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management. Am J Hematol. 2017; 92:1243-59. DOI: https://doi.org/10.1002/ajh.24880

Shomali W, Gotlib J. World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024;99:946-68. DOI: https://doi.org/10.1002/ajh.27287

Valent P, Klion AD, Horny HP, Roufosse F, Gotlib J, Weller PF, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012; 130:607-12.e9. DOI: https://doi.org/10.1016/j.jaci.2012.02.019

Klion AD. How I treat hypereosinophilic syndromes. Blood. 2015;126:1069-77. DOI: https://doi.org/10.1182/blood-2014-11-551614

Roufosse F, Kahn JE, Rothenberg ME, Wardlaw AJ, Klion AD, Kirby SY, et al. Efficacy and safety of mepolizumab for the treatment of hypereosinophilic syndrome: a multicentre, double-blind, placebo-controlled, phase 3 trial. J Allergy Clin Immunol. 2020;146:1397-405. DOI: https://doi.org/10.1016/j.jaci.2020.08.037

Downloads

PDF (Português)

Published

2025-08-06

How to Cite

Gomes M, Ferreira S, Mendes A, Marques T, Silva S. A Case of Idiopathic Hypereosinophilic Syndrome Treated with Mepolizumab. Acta Med Port [Internet]. 2025 Aug. 6 [cited 2025 Dec. 6];38(9):588-9. Available from: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/23406

Download Citation

Issue

Vol. 38 No. 9 (2025): September

Section

Letters to the Editor

License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.

It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.

Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.

After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.